REAL TIME BioIT World Conference Coverage for Scientific & Social Media: April 29 – May 1, 2014, Seaport World Trade Center, Boston, MA
Curator: Aviva Lev-Ari, PhD, RN
Conference Agenda
http://www.bio-itworldexpo.com/uploadedFiles/Bio-IT_World_Expo/Agenda/14/2014-BIT-Brochure.pdf
BioIT World Conference Coverage for Scientific & Social Media in REAL TIME
by
Aviva Lev-Ari, PhD, RN
PLENARY KEYNOTE PRESENTATIONS: TUESDAY, APRIL 29 | 4:00 – 5:00 PM @ BioIT World, April 29 – May 1, 2014 Seaport World Trade Center, Boston, MA
PLENARY KEYNOTE PRESENTATIONS: WEDNESDAY, APRIL 30 | 8:00 – 9:45 AM @ BioIT World, April 29 – May 1, 2014 Seaport World Trade Center, Boston, MA
AWARDS: Best of Show Awards, Best Practices Awards and 2014 Benjamin Franklin Award @ BioIT World, April 29 – May 1, 2014 Seaport World Trade Center, Boston, MA
Track 4 Bioinformatics: Utilizing Massive Quantities of –omic Information across Research Initiatives @ BioIT World, April 29 – May 1, 2014 Seaport World Trade Center, Boston, MA
Track 5 Next-Gen Sequencing Informatics: Advances in Analysis and Interpretation of NGS Data @ BioIT World, April 29 – May 1, 2014 Seaport World Trade Center, Boston, MA
Track 6 Systems Pharmacology: Pathways to Patient Response @ BioIT World, April 29 – May 1, 2014 Seaport World Trade Center, Boston, MA
Track 11 Collaboration and Externalization in R&D @ BioIT World, April 30, 2014 Seaport World Trade Center, Boston, MA
Selective Events that Occurred and were NOT covered in REAL TIME
PLENARY KEYNOTE PRESENTATIONS: THURSDAY, MAY 1 | 8:00 – 10:00 AM @ BioIT World, April 29 – May 1, 2014 Seaport World Trade Center, Boston, MA
http://pharmaceuticalintelligence.com/?p=22201&preview=true
Track 9 Pharmaceutical R&D Informatics: Collaboration, Data Science and Biologics @ BioIT World, April 29 – May 1, 2014 Seaport World Trade Center, Boston, MA
http://pharmaceuticalintelligence.com/?p=22210&preview=true
Track 12 Cancer Informatics: Applying Computational Biology to Cancer Research & Care @ BioIT World, April 29 – May 1, 2014 Seaport World Trade Center, Boston, MA
http://pharmaceuticalintelligence.com/?p=22204&preview=true
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.